Akoya Biosciences, Inc.

NasdaqGS:AKYA Stock Report

Market Cap: US$122.8m

Akoya Biosciences Future Growth

Future criteria checks 1/6

Akoya Biosciences is forecast to grow earnings and revenue by 41.7% and 12.3% per annum respectively. EPS is expected to grow by 46.9% per annum. Return on equity is forecast to be -173.1% in 3 years.

Key information

41.7%

Earnings growth rate

46.9%

EPS growth rate

Life Sciences earnings growth17.8%
Revenue growth rate12.3%
Future return on equity-173.1%
Analyst coverage

Good

Last updated14 Aug 2024

Recent future growth updates

Akoya Biosciences, Inc. (NASDAQ:AKYA) Just Reported, And Analysts Assigned A US$5.42 Price Target

Aug 09
Akoya Biosciences, Inc. (NASDAQ:AKYA) Just Reported, And Analysts Assigned A US$5.42 Price Target

Recent updates

Akoya Biosciences, Inc. (NASDAQ:AKYA) Just Reported, And Analysts Assigned A US$5.42 Price Target

Aug 09
Akoya Biosciences, Inc. (NASDAQ:AKYA) Just Reported, And Analysts Assigned A US$5.42 Price Target

Market Might Still Lack Some Conviction On Akoya Biosciences, Inc. (NASDAQ:AKYA) Even After 31% Share Price Boost

Jun 27
Market Might Still Lack Some Conviction On Akoya Biosciences, Inc. (NASDAQ:AKYA) Even After 31% Share Price Boost

Is Akoya Biosciences (NASDAQ:AKYA) A Risky Investment?

Jun 24
Is Akoya Biosciences (NASDAQ:AKYA) A Risky Investment?

We Think Shareholders Are Less Likely To Approve A Large Pay Rise For Akoya Biosciences, Inc.'s (NASDAQ:AKYA) CEO For Now

May 29
We Think Shareholders Are Less Likely To Approve A Large Pay Rise For Akoya Biosciences, Inc.'s (NASDAQ:AKYA) CEO For Now

Investors Continue Waiting On Sidelines For Akoya Biosciences, Inc. (NASDAQ:AKYA)

May 10
Investors Continue Waiting On Sidelines For Akoya Biosciences, Inc. (NASDAQ:AKYA)

Is Akoya Biosciences (NASDAQ:AKYA) Weighed On By Its Debt Load?

Feb 28
Is Akoya Biosciences (NASDAQ:AKYA) Weighed On By Its Debt Load?

Investors Still Aren't Entirely Convinced By Akoya Biosciences, Inc.'s (NASDAQ:AKYA) Revenues Despite 31% Price Jump

Nov 25
Investors Still Aren't Entirely Convinced By Akoya Biosciences, Inc.'s (NASDAQ:AKYA) Revenues Despite 31% Price Jump

Akoya Biosciences Seeks Growth Despite Higher Operating Losses

May 30

Akoya Biosciences, Inc. (NASDAQ:AKYA) Just Reported First-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?

May 11
Akoya Biosciences, Inc. (NASDAQ:AKYA) Just Reported First-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?

Akoya Biosciences and AstraZeneca ink collaboration agreement

Jun 04

Earnings and Revenue Growth Forecasts

NasdaqGS:AKYA - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/2026134-190N/A7
12/31/2025116-30-2-38
12/31/202498-51-35-289
6/30/202493-60-54-51N/A
3/31/202494-68-56-52N/A
12/31/202397-63-55-51N/A
9/30/202391-71-59-55N/A
6/30/202385-76-61-54N/A
3/31/202379-73-62-55N/A
12/31/202275-71-61-53N/A
9/30/202270-69-57-49N/A
6/30/202264-63-57-51N/A
3/31/202260-51-55-50N/A
12/31/202155-44-41-36N/A
9/30/202152-34-37-32N/A
6/30/202148-28-24-21N/A
3/31/202144-28-13-10N/A
12/31/202042-22-10-7N/A
12/31/201942-18-17-14N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: AKYA is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: AKYA is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: AKYA is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: AKYA's revenue (12.3% per year) is forecast to grow faster than the US market (8.8% per year).

High Growth Revenue: AKYA's revenue (12.3% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: AKYA is forecast to be unprofitable in 3 years.


Discover growth companies